Lei Di Network Lei Jianping May 5th
Sanbo Brain Hospital Management Group Co., Ltd. (abbreviation: "Sanbo Brain", stock code: 301293) was listed on the Growth Enterprise Market of Shenzhen Stock Exchange today.
Sanbo Brain Technology issued 39.6129 million shares at an issue price of 29.6 yuan and raised 1.173 billion yuan.
Sanbo Brain Science originally planned to raise 500 million yuan, of which 300 million yuan was used for the Hunan Sanbo Brain Hospital project, 70.1 million yuan was used for the Sanbo Brain Science information construction project, and 130 million yuan was used to supplement working capital.
This means that Sanbo Brain Science has raised more than 600 million yuan.
The opening price of Sanbo Brain Technology was 50.11 yuan, a 69.3% increase from the issue price; the closing price was 52.5 yuan, a 77.36% increase from the issue price; based on the closing price, the company’s market value was 8.319 billion yuan.
Annual revenue of 1.068 billion
Sanbo Brain Science was founded in 2003 by neuromedical experts Luan Guoming, Yu Chunjiang, Shi Xiangen, and senior medical management expert Zhang Yang. "In one medical group.
Sanbo Brain Science takes neurology as the leader, strengthens the development model of specialties and small comprehensive, and forms a medical service network covering the core areas of the country. The service diseases cover various neurological diseases such as brain tumors, cerebrovascular, functional neurosurgery, spinal cord, and pediatric brain and brain diseases, as well as gynecology, pediatrics, internal medicine, surgery, pain, general medicine and other diseases.
According to the prospectus, Sanbo Brain's revenue in 2020, 2021, and 2022 will be 987 million yuan, 1.137 billion yuan, and 1.068 billion yuan respectively; net profits will be 74.079 million yuan, 87.3778 million yuan, and 76.78 million yuan; The net profits were 67.7128 million yuan, 74.3596 million yuan, and 52.07 million yuan, respectively.
Sanbo Brain Technology expects revenue in the first quarter of 2023 to be 292 million yuan, an increase of 10.03% from 265 million yuan in the same period of the previous year; net profit of 18.59 million, an increase of 28.85% from 14.4284 million yuan in the same period of the previous year; net profit after deducting non-existing expenses It was 17.59 million yuan, an increase of 31.65% compared with 13.36 million yuan in the same period of last year.
TBP and Taikang Life are shareholders
The controlling shareholders and actual controllers of Sanbo Brain are Zhang Yang, Luan Guoming, Yu Chunjiang and Shi Xiangen. The above-mentioned shareholders exercise joint control over the company through the "Action in Concert Agreement", holding a total of 34.6472 million shares, with a shareholding ratio of 29.15%.
Before the IPO, Zhang Yang held 14.12%, Yu Chunjiang and Luan Guoming each held 5.56%, Shi Xiangen held 3.91%, TBP held 20.93%, Taikang Life Insurance held 6.31%, and Lin Ruiyan held 4.28% %, Ningbo Investment and Kaitai Borui hold 3.94% of the shares respectively, Xinde Longyan holds 3.08% of the shares, Yang Hongpeng holds 3.07% of the shares, and Bokang Hengtai holds 2.76% of the shares;
Bochuang Shengxiang holds 2.72%, Vaucluse Capital holds 2.31%, Yingtan Investment holds 2.13%, Yingxinda Investment holds 1.98%, Boda Xincheng holds 1.81%, Boren Yutai holds is 1.58%, and Yikai Fund holds 1.26%.
Zhang Yang, born in October 1965, graduated from Beijing Institute of Technology with a bachelor's degree in 1988; in 1999, graduated from Beijing Institute of Technology with a master's degree; in 2007, graduated from Guanghua School of Management, Peking University with an executive master's degree in business administration. From 1988 to 1992, worked in Beijing Camera General Factory and Beijing Haidian Beike Instrument Factory; from 1992 to 2004, served as the chairman and general manager of Beijing Beike Digital Medical Technology Co., Ltd.; from 2004 to 2014, served as General Manager of Sanbo Brain Science; since 2014, he has served as Chairman and General Manager of Sanbo Brain Science.
Luan Guoming, born in September 1959, has permanent residency in the United States. In 1992, he graduated from Beijing Tiantan Hospital affiliated to Capital Medical University and Beijing Institute of Neurosurgery (Beijing) with a doctorate in neurosurgery. From 1982 to 1986, resident doctor in surgery and neurosurgery at the Affiliated Hospital of Jiamusi Medical College; from 1987 to 1989, attending doctor and lecturer in neurosurgery in the First Affiliated Hospital of China Medical University; from 1989 to 1992, attending doctor in neurosurgery in Beijing Tiantan Hospital Teacher; from 1992 to 1994, assistant researcher and postdoctoral fellow in neurosurgery, University of California, Los Angeles School of Medicine; from 1994 to 1998, deputy director of neurosurgery and functional neurosurgery, Beijing Tiantan Hospital, associate professor, master supervisor, Beijing Neurology Director of the Department of Neurobiology, Institute of Surgery;
From 1998 to 2002, Luan Guoming served as the Chief Physician, Professor and Doctoral Supervisor of Neurosurgery and Functional Neurosurgery of Beijing Tiantan Hospital; from 2003 to 2004, he served as the Chief Physician, Professor and Doctoral Supervisor of Neurosurgery of Beijing Hospital of the Ministry of Health. Director of the Biochemical Blood Lipid Department of the Institute of Geriatric Diseases of the Ministry of Health; since 2004, he has served as director of Sanbo Brain Hospital, professor, doctoral supervisor, chief physician, chief expert of Sanbo Brain Hospital of Capital Medical University, and director of the third department of the School of Surgery of Capital Medical University.
Yu Chunjiang, born in December 1955, graduated from Capital Medical University with a doctorate in neurosurgery in 1992. From 1988 to 2004, he successively served as the attending physician, deputy chief physician, chief physician, associate professor, professor, and administrative deputy director of Beijing Tiantan Hospital Affiliated to Capital Medical University, director of the neuroanatomy laboratory of Beijing Institute of Neurosurgery, among them, from 1993 to 1995 In 2004, he was a postdoctoral fellow in neurosurgery at the University of Florida School of Medicine; since 2004, he has served as a director of Sanbo Brain Hospital, a professor, doctoral supervisor, chief physician, and chief expert at Sanbo Brain Hospital of Capital Medical University.
After the IPO, Zhang Yang held 10.59%, Yu Chunjiang and Luan Guoming each held 4.17%, Shi Xiangen held 2.93%, TBP held 15.7%, Taikang Life Insurance held 4.74%, and Lin Ruiyan held 3.21% %, Ningbo Investment and Kaitai Borui hold 2.95% of the shares respectively, Xinde Longyan holds 2.31% of the shares, Yang Hongpeng holds 2.3% of the shares, and Bokang Hengtai holds 2.07% of the shares;
Bochuang Shengxiang holds 2.04%, Vaucluse Capital holds 1.74%, Yingtan Investment holds 1.6%, Yingxinda Investment holds 1.48%, Boda Xincheng holds 1.36%, Boren Yutai holds is 1.18%, and Yikai Fund holds 0.95%.
———————————————
Lei Di was founded by Lei Jianping, a media person. If you reprint, please indicate the source.
